Longitudinal changes in type 2 and Aspergillus-specific biomarkers during omalizumab therapy for allergic bronchopulmonary aspergillosis: a 36-week study in Chinese patients

Peize Liu, Mengwei Wu, Xu Li, Xiao Xu, Haoyuan Li, Xueli Dong, Yanmeng Kang, Jianxue Bai, Chao Wang, He Geng, Ling Zhou, Yan Sun, Na Zhang, Yunqing Zhang, Na Liu, Tingting Gao, Liang Dong, Fen Liu, Lili Zhi

Open source

DOI: 10.3389/fimmu.2026.1936285
Published: 2026-10-26
Container: Frontiers in Immunology
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1936285,
  title = {Longitudinal changes in type 2 and Aspergillus-specific biomarkers during omalizumab therapy for allergic bronchopulmonary aspergillosis: a 36-week study in Chinese patients},
  author = {Peize Liu and Mengwei Wu and Xu Li and Xiao Xu and Haoyuan Li and Xueli Dong and Yanmeng Kang and Jianxue Bai and Chao Wang and He Geng and Ling Zhou and Yan Sun and Na Zhang and Yunqing Zhang and Na Liu and Tingting Gao and Liang Dong and Fen Liu and Lili Zhi},
  year = {2026},
  journal = {Frontiers in Immunology},
  doi = {10.3389/fimmu.2026.1936285},
  url = {https://doi.org/10.3389/fimmu.2026.1936285}
}

RIS

TY  - JOUR
TI  - Longitudinal changes in type 2 and Aspergillus-specific biomarkers during omalizumab therapy for allergic bronchopulmonary aspergillosis: a 36-week study in Chinese patients
AU  - Peize Liu
AU  - Mengwei Wu
AU  - Xu Li
AU  - Xiao Xu
AU  - Haoyuan Li
AU  - Xueli Dong
AU  - Yanmeng Kang
AU  - Jianxue Bai
AU  - Chao Wang
AU  - He Geng
AU  - Ling Zhou
AU  - Yan Sun
AU  - Na Zhang
AU  - Yunqing Zhang
AU  - Na Liu
AU  - Tingting Gao
AU  - Liang Dong
AU  - Fen Liu
AU  - Lili Zhi
PY  - 2026
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1936285
UR  - https://doi.org/10.3389/fimmu.2026.1936285
ER  -

APA

Liu, P., Wu, M., Li, X., Xu, X., Li, H., Dong, X., Kang, Y., Bai, J., Wang, C., Geng, H., Zhou, L., Sun, Y., Zhang, N., Zhang, Y., Liu, N., Gao, T., Dong, L., Liu, F., & Zhi, L. (2026). Longitudinal changes in type 2 and Aspergillus-specific biomarkers during omalizumab therapy for allergic bronchopulmonary aspergillosis: a 36-week study in Chinese patients. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1936285

Source records

crossref · retrieved 2026-11-10T20:17:23.233Z